| Timeslot | Topic | Speaker | |
|---|---|---|---|
| 17.00 - 18.00 | Registration/ Snack | ||
| 18.00 - 18.10 | Welcome to Cells to Surgery 2019 | ||
| 18.10 - 18.50 | Neo-adjuvant therapy for melanoma | Alexander van Akkooi | NKI-AvL, Amsterdam |
| 18.50 - 19.25 | Gut microbiome and response to anti-PD-1 | Jennifer Wargo | MD Anderson Cancer Center, Houston |
| 19.25 20.00 | Systemic therapy for merkel cell carcinoma | Hilde Jalving | UMCG, Groningen |
| 20.00 | Diner |
| Timeslot | Topic | Speaker | |
|---|---|---|---|
| 9.00 - 9.20 | Controverses in melanoma pathology | Antien Mooyaart | Erasmus MC, Rotterdam |
| 9.20 - 9.50 | Impact of 8th AJCC on melanoma outcomes | Max Madu | NKI-AvL, Amsterdam |
| 9.50 - 10.20 | Adjuvant immunotherapy in melanoma | Lex Eggermont | Institute Gustave-Roussy, Paris |
| 10.20 - 10.50 | Triple therapy in melanoma: more is better? | Andrew Furness | Royal Marsden Hospital, London |
| 10.50 - 11.20 | Coffee Break | ||
| 11.20 - 11.40 | Mohs micrographic surgery for squamous cell carcinoma | Renate van den Bos | Erasmus MC, Rotterdam |
| 11.40 - 12.00 | Sentinel Node procedure for NMSC in head and neck region. | Michiel van den Brekel | NKI-AvL, Amsterdam |
| 12.00 - 12.20 | Isolated limb perfusion in CSCC | Eva Huis in ’t Veld | NKI-AvL, Amsterdam |
| 12.20 - 12.50 | Anti-PD1 treatment in advanced CSCC | Dirk Schadendorf | University Hospital Essen |
| 12.50-14.10 | Lunch | ||
| 14.10 - 14.40 | How to best deal with drug pricing and drug costs | Carin Uyl de Groot | Erasmus University, Rotterdam |
| 14.40 - 15.00 | Prognosis of Merkel cell carcinoma | Linde van Veenendaal | NKI-AvL, Amsterdam |
| 15.00 - 15.30 | Pro Contra debate Adjuvante TT vs. adjuvante IO voor BRAF+ stadium III melanoom | Astrid van der Veldt & Karijn Suijkerbuijk | Erasmus MC, Rotterdam UMCU, Utrecht |
| 15.30 – 16.10 | Coffee Break | ||
| 16.10 - 16.40 | Pro Contra debate Locoregional therapy vs. systemic therapy for in transit metastasis | Dirk Grünhagen & Hans Westgeest | NKI-AvL, Amsterdam / Amphia ziekenhuis Breda |
| 16.40 - 17.00 | Melanoma treatment in immunocompromised patients | Arjen Joosse | Erasmus MC, Rotterdam |
| 17.00 - 17.20 | Role of TVEC in melanoma treatment | Viola Franke | NKI-AvL, Amsterdam |
| 17.20- 17.40 | Treatment of melanoma brain mets | Martin van den Bent | Erasmus MC, Rotterdam |
| 17.40 - 18.00 | Organisation of melanoma care (in The Netherlands) | TBA | |
| Timeslot | Topic | Speaker | |
|---|---|---|---|
| 8.45 - 9.05 | Melanoma mortality: the Breslow paradox | Loes Hollestein | Erasmus MC, Rotterdam |
| 9.05 - 9.35 | What to do with stage II melanoma? | Lex Eggermont | Gustave-Roussy Institute, Paris |
| 9.35 - 9.55 | Risk of melanoma in lentigo maligna | Judith Zoutendijk | Erasmus MC, Rotterdam |
| 9.55 - 10.15 | Skin cancer mortality in transplant recipients | Jan Nico Bouwes Bavinck | LUMC, Leiden |
| 10.15 - 10.45 | Coffee Break | ||
| 10.45 - 11.15 | Basal cell carcinoma; genetics and clinical implications | Klara Mosterd | MUMC, Maastricht |
| 11.15 - 11.35 | Skin cancer costs in The Netherlands | Eline Noels | Erasmus MC, Rotterdam |
| 11.35 - 11.55 | Comparative RCT of topical AK therapies: 1 year results. | Maud Jansen | MUMC, Maastricht |
| 11.55 - 12.20 | Genetic Influence on Skin Cancer and Nevus Count | Veronique Bataille | King's College London, London |
| 12.20 - 13.30 | Lunch | ||
| 13.30 - 13.50 | Prognostic factors of CSCC progression: recent insights from UK. | Tamar Nijsten | Erasmus MC, Rotterdam |
| 13.50 - 14.10 | Views and opinions of Patinets and providers on skin cancer care | Sven van Egmond | Erasmus MC, Rotterdam |
| 14.10 - 14.30 | The expansion of Mohs micrographic surgery in The Netherlands | Marcus Muche | Mohs klinieken, Hoorn |
| 14.30 - 14.50 | Tips & tricks of complex reconstruction in head and neck region. | Koen Ingels | Radboud UMC, Nijmegen |
| 14.50 – 15.20 | Staging issues of cutaneous squamous cell carcinoma | Chrysalyne Schmults | Brigham and Women’s hospital, Boston |
| 15.20 | Closure of Cells to Surgery 2019 | ||
